Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The principal aim of this study is to determine whether a novel biopsychosocial intervention following opioid overdose (OD) affects 1) the frequency of secondary opioid OD events and 2) the proportion of individuals who remain engaged in treatment for opioid use disorder (OUD) or are in remission at 30 days and at 180 days post intervention. Remission is defined as engagement in daily medication-assisted therapy (MAT)-typically buprenorphine/naloxone (BUP) or methadone- and/or a recovery capital score of ≥ 27.5. The intervention principally involves connecting OUD-affected individuals with community resources, including BUP-, MAT-, and education-related services. To carry out the intervention, an addiction recovery coach and an appropriately trained health-educator paramedic (research assistant) will form a team and perform follow-up visits (electronically/remotely and/or by phone) after a participant has experienced at least 1 opioid OD requiring naloxone resuscitation. Our hypothesis is that the intervention will decrease subsequent OD events and increase the likelihood of remission. To evaluate this hypothesis, data will be collected from self-report and from EPIC, Yale New Haven Hospital's medical record system. The secondary aim is to determine whether the intervention affects 1) the frequency of positive-urine tests for opioids and 2) the frequency and proportion of subjects self-reporting opioid use. Our hypothesis is that our intervention will decrease both. Data from the entire cohort will be compared in aggregate with patients who were started on BUP in the ED over the same time period and with historic controls.
Description: Frequency of positive urine tests at 30 days after intervention (data obtained via chart review)
Measure: Frequency of positive urine tests at 30 days (chart review) Time: 30 days post interventionDescription: Frequency of positive urine tests at 180 days after intervention (data obtained via chart review)
Measure: Frequency of positive urine tests at 180 days (chart review) Time: 180 days post interventionDescription: Frequency of positive urine tests at 30 days after intervention (data obtained via self-report)
Measure: Frequency of positive urine tests at 30 days (self-report) Time: 30 days post interventionDescription: Frequency of positive urine tests at 180 days after intervention (data obtained via self-report)
Measure: Frequency of positive urine tests at 180 days (self-report) Time: 180 days post interventionDescription: Percentage of positive urine tests at 30 days after intervention (data obtained via chart review)
Measure: Percentage of positive urine tests at 30 days (chart review) Time: 30 days post interventionDescription: Percentage of positive urine tests at 180 days after intervention (data obtained via chart review)
Measure: Percentage of positive urine tests at 180 days (chart review) Time: 180 days post interventionDescription: Percentage of positive urine tests at 30 days after intervention (data obtained via chart review)
Measure: Percentage of positive urine tests at 30 days (self-report) Time: 30 days post interventionDescription: Percentage of positive urine tests at 180 days after intervention (data obtained via self-report)
Measure: Percentage of positive urine tests at 180 days (self-report) Time: 180 days post interventionAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports